U.S. Chemicals Stock News

NasdaqGS:SENS
NasdaqGS:SENSMedical Equipment

Senseonics Holdings (SENS) Is Up 27.7% After Q3 Revenue Surge and Record New Patient Growth Has the Bull Case Changed?

On October 6, 2025, Senseonics Holdings announced preliminary unaudited revenue for the third quarter ended September 30, reporting approximately US$8.1 million, an increase of 91% over the same period in 2024, primarily attributed to roughly 160% new patient growth in the U.S. This upturn in both revenue and new patient adoption highlights more robust market traction, suggesting a potential acceleration in demand for the company’s continuous glucose monitoring systems. We’ll now explore how...
NYSE:KNF
NYSE:KNFBasic Materials

Is Knife River’s Share Slide Justified After $500 Million Infrastructure Contract Win?

If you're standing at the crossroads of what to do with your Knife River shares or thinking of putting some capital to work, you're not alone. Knife River’s recent performance has grabbed the attention of both cautious investors and opportunists, sparking plenty of debate on whether the current price fairly reflects the company’s long-term prospects. Knife River's stock price has seen a difficult stretch lately. Down 3.9% in the last week, 11.6% in the last month, and a hefty 29.2%...
NasdaqGM:ACIU
NasdaqGM:ACIUBiotechs

AC Immune (NasdaqGM:ACIU): Exploring Valuation Following Promising Phase 1b/2a Alzheimer’s Data Publication

AC Immune (NasdaqGM:ACIU) just shared peer-reviewed data from its Phase 1b/2a trial of ACI-35.030, an active immunotherapy targeting Tau in early Alzheimer's, developed with Janssen. The findings highlight a rapid and sustained antibody response as well as a clean safety profile. See our latest analysis for AC Immune. With this encouraging clinical update, AC Immune is starting to turn heads, especially as the company’s latest innovation underscores its growing potential in Alzheimer’s...
NYSE:IPG
NYSE:IPGMedia

How Bayer’s Global Creative Agency Deal Has Changed Interpublic Group’s (IPG) Investment Story

In September 2025, Bayer’s Consumer Health division announced it had selected Interpublic Group as its exclusive global creative, production, and media agency partner for iconic self-care brands including Aspirin and Claritin. This partnership signals Bayer’s commitment to integrated marketing powered by GenAI for both global consistency and tailored local consumer engagement. We'll review how IPG’s appointment as Bayer’s lead global partner could strengthen its client portfolio and...
NYSE:KVYO
NYSE:KVYOSoftware

US High Growth Tech Stocks to Watch in October 2025

As of October 2025, the U.S. stock market is experiencing a notable upswing, with both the Nasdaq and S&P 500 reaching new closing highs despite ongoing government shutdown concerns. This positive momentum in major indices highlights investor optimism, particularly in high-growth sectors like technology, where companies are often characterized by innovative products and robust potential for future expansion.
NasdaqGS:CRDO
NasdaqGS:CRDOSemiconductor

Three High Growth Stocks With Strong Insider Confidence

As the Nasdaq and S&P 500 reach new closing highs, buoyed by significant tech deals and a resilient market response to the ongoing U.S. government shutdown, investors are increasingly focused on stocks that demonstrate both robust growth potential and strong insider confidence. In this thriving market environment, companies with high insider ownership often signal enduring trust in their long-term prospects, making them compelling considerations for those looking to align with informed...
NYSE:APAM
NYSE:APAMCapital Markets

Top Dividend Stocks Featuring Artisan Partners Asset Management

As the U.S. stock market continues to reach new heights, with the Nasdaq and S&P 500 posting record closing highs, investors are increasingly seeking opportunities that offer both growth potential and reliable income streams. In this vibrant economic landscape, dividend stocks stand out as a compelling choice for those looking to balance risk and reward while capitalizing on consistent returns.